Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ENMD-2076 |
Synonyms | |
Therapy Description |
ENMD-2076 has selective inhibitory activity against Aurora kinase A and FLT3, with reduced potency against RET, KDR (VEGFR2), FGFR1, and FGFR2, preventing angiogenesis and decreasing cell proliferation (PMID: 21177375, PMID: 22921155, PMID: 32154962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ENMD-2076 | ENMD 2076|ENMD2076 | Aurka Inhibitors 27 FGFR1 Inhibitor 28 FGFR2 Inhibitor 23 FLT3 Inhibitor 69 RET Inhibitor 53 VEGFR2 Inhibitor 37 | ENMD-2076 has selective inhibitory activity against Aurora kinase A and FLT3, with reduced potency against RET, KDR (VEGFR2), FGFR1, and FGFR2, preventing angiogenesis and decreasing cell proliferation (PMID: 21177375, PMID: 22921155, PMID: 32154962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCA4 inact mut | lung non-small cell carcinoma | sensitive | ENMD-2076 | Preclinical - Cell culture | Actionable | In a preclinical study, a non-small cell lung cancer cell line harboring an inactivating mutation in SMARCA4 demonstrated sensitivity to ENMD-2076 in culture (PMID: 28102363). | 28102363 |
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | ENMD-2076 | Phase I | Actionable | In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). | 27406088 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01639248 | Phase II | ENMD-2076 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | Completed | USA | 1 |
NCT02234986 | Phase II | ENMD-2076 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | Completed | USA | 0 |
NCT01719744 | Phase II | ENMD-2076 | Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | Completed | CAN | 0 |
NCT01914510 | Phase II | ENMD-2076 | A Study of ENMD-2076 in Ovarian Clear Cell Cancers | Completed | CAN | 0 |